Maze Therapeutics Signs an Exclusive Worldwide License Agreement with Sanofi for MZE001 to Treat Pompe Disease
- Maze will receive $150M up front in cash & future equity investment to further develop and commercialize MZE001 & will be eligible to receive an additional ~$600M in development, regulatory and sales milestones along with royalties on sales if MZE001 is successfully commercialized
- Maze gets an exclusive license to related GYS1-targeting backup programs and intellectual property. Sanofi will be responsible for launching a P-II trial in 2023
- MZE001 was found to be well-tolerated & reduced glycogen accumulation in blood cells and muscle in healthy volunteers in the first-in-human, single, and multiple ascending dose trials. MZE001, an oral glycogen synthase inhibitor & is currently in development for Pompe disease & other indications
Ref: Businesswire | Image: Maze Therapeutics
Neha is a Senior Editor at PharmaShots. She is passionate and very enthusiastic about recent updates and developments in the life sciences and pharma industry. She covers Biopharma, MedTech, and Digital health segments along with different reports at PharmaShots. She can be contacted at firstname.lastname@example.org.